Latest Content

Krieger Scientific's Joseph Morwald explains how siloed departments, disconnected systems, and a lack of cross-functional accountability are creating the structural compliance gaps that FDA warning letters keep exposing.

The AstraZeneca-BMS rumors have reframed how the industry thinks about scale, capability, and competitive advantage.

From Lilly's blockbuster earnings to a first-of-its-kind narcolepsy approval, a new mRNA flu vaccine, and a potential mega-merger that would reshape the industry — here's what you need to know.

In today's Pharmaceutical Executive Daily, an antitrust attorney weighs the legal risks of a hypothetical AstraZeneca-Bristol Myers Squibb merger, Eli Lilly beats Wall Street estimates on soaring Mounjaro and Zepbound sales and raises its full-year guidance, and the FDA approves Moderna's first mRNA-based flu vaccine for adults 50 and older.

Ron Lanton, senior partner at Lanton, Lanton & Sosa Law, discusses the legal risks associated with a hypothetical AstraZeneca–Bristol Myers Squibb merger.

FDA has approved Takeda's Orzeyful as the first oral orexin receptor 2 agonist for narcolepsy type 1 in adults.

Eli Lilly posted $23 billion in second-quarter revenue driven by Mounjaro's sales surge to $9.94 billion and Zepbound's $4.93 billion.

The FDA has approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based influenza vaccine, for use in adults 50 and older.

Financials explain BMS' interest, but not why AstraZeneca would accept the risks and scrutiny of the rumored mega-merger discussions.

In today's Pharmaceutical Executive Daily, a senior source denies reports of merger talks between AstraZeneca and Bristol Myers Squibb, CSPC Pharmaceutical and AstraZeneca form a joint venture for biologics manufacturing in China, and a feature examines how U.S. Patent and Trademark Office policy changes are slowing patent challenges for generic and biosimilar drugmakers.

The rumors of reported AstraZeneca–Bristol Myers merger discussions provide an opportunity to examine how multiple emerging capabilities may reshape corporate strategy, mergers and acquisitions, and long-term competitive advantage.

A senior source claims there are no discussions underway between AstraZeneca and Bristol Myers Squibb over a potential combination.

CSPC Pharmaceutical and AstraZeneca have formed a 51:49 joint venture to build a biologics manufacturing facility in Shijiazhuang.